Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) Director Carl Dambkowski sold 105,000 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $58.97, for a total transaction of $6,191,850.00. Following the transaction, the director owned 73,743 shares in the company, valued at approximately $4,348,624.71. The trade was a 58.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oruka Therapeutics Stock Performance
Shares of ORKA traded up $1.92 during trading hours on Friday, reaching $60.61. 928,774 shares of the company traded hands, compared to its average volume of 1,066,667. The stock’s fifty day moving average is $57.20 and its 200 day moving average is $40.29. Oruka Therapeutics, Inc. has a 1-year low of $10.64 and a 1-year high of $91.00. The stock has a market cap of $3.66 billion, a P/E ratio of -31.24 and a beta of -0.20.
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. On average, equities research analysts predict that Oruka Therapeutics, Inc. will post -2.05 EPS for the current year.
Wall Street Analyst Weigh In
Read Our Latest Analysis on Oruka Therapeutics
Institutional Trading of Oruka Therapeutics
A number of large investors have recently bought and sold shares of ORKA. Viking Global Investors LP bought a new position in shares of Oruka Therapeutics during the third quarter valued at $51,280,000. Paradigm Biocapital Advisors LP bought a new stake in shares of Oruka Therapeutics in the 4th quarter worth about $51,840,000. Remedium Capital Partners LLC acquired a new stake in shares of Oruka Therapeutics during the 4th quarter worth about $47,054,000. Avoro Capital Advisors LLC acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth about $25,640,000. Finally, Deep Track Capital LP lifted its holdings in Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after purchasing an additional 735,983 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors.
Oruka Therapeutics Company Profile
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Read More
- Five stocks we like better than Oruka Therapeutics
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
